Abstract:Abstract Objectives: To identify and describe the clinicopathologic features characterizing a set of patients with nodal marginal zone lymphoma (N-MZL) positive for expression of CD23 and to contrast findings against those of a cohort of patients with CD23-negative N-MZL. Methods: Cases of N-MZL diagnosed over a 20-year interval were identified from the medical record and allocated to two cohorts based on immunophenotypic expression of CD23. Clinical, morphologic, immunophenotypic and cytogenetic data were retrospectively reviewed. Results: Twenty-six cases with histological and immunophenotypic findings typical of N-MZL were identified, 12 of which expressed CD23 by flow cytometry or immunohistochemistry. In the CD23-positive N-MZL cohort, only 2/12 (17%) of patients demonstrated multicompartment lymphadenopathy and another 3/12 (25%) demonstrated bone marrow involvement, with an Ann Arbor disease stage IV. In the CD23-negative cohort, 8/14 (57%) patients presented with multicompartment lymphadenopathy and an additional 6/14 (43%) demonstrated bone marrow involvement, with an Ann Arbor disease stage IV. The average follow-up period for all patients (CD23-positive and CD23-negative cohorts) was 6.7 years (range: 1-17; IQR: 10). In the CD23-positive disease cohort, treatment and follow-up data were recorded for 10/12 (83%) patients. Three patients were followed without intervention, one of which transformed to an aggressive lymphoma. This patient was treated with a series of rituximab-based chemotherapies and remains well two years post stem cell transplant. One patient was surgically managed with adjuvant radiation and remains well with no evidence of disease. Six others were treated with various rituximab-based chemotherapy regimens. Two died secondary to sequalae related to progression of their disease. The others remain alive and well with no evidence of active disease. In the CD23-negative disease cohort, treatment and follow-up data were recorded for 13/14 (93%) patients. For seven patients in this cohort followed by observation only, five were alive and well at last follow-up. Two were deceased due to unrelated causes. For those otherwise treated, there was only a single fatality due to progression of disease. Comparing the two cohorts, those with CD23-positive disease were significantly more likely to present with a lower Ann Arbor stage (p=0.0155) and FLIPI score (p=0.0086). However, neither 5-year (p=0.6908) nor overall survival (p=0.5956) were significantly different between the two cohort medians. Conclusions: CD23 expression in our cohort of N-MZL patients correlated with greater likelihood of single versus multiple compartment lymphadenopathy, restriction of lymphadenopathy to the head and neck regions, lower Ann Arbor stage, and lower FLIPI score. The data here, while derived from a limited cohort, demonstrates that CD23 correlates with a lower-grade clinical assessment at time of disease presentation but is associated with a more rapid clinical decline given a lack of evidence for survival benefits in the long term.

Immunohistochemical determination of CD23 expression in Hodgkin's disease using paraffin section

Methods in pathology. Identification of T-cell lymphomas in paraffin-embedded tissues using polyclonal anti-CD3 antibody: comparison with frozen section immunophenotyping and genotypic analysis.

Application of Rabbit Monoclonal Antibody GCET2 in Diagnosis of Diffuse Large B Cell Lymphoma

Demonstration of Distinct Antigenic Profiles of Small B-Cell Lymphomas by Paraffin Section Immunohistochemistry

[The Expression of CD19 in 210 Cases of Childhood Acute Leukemia and Its Significance].

Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry

Expression of CD19 in 321 Cases of Acute Leukemia

Clinicopathologic Features of CD23-Positive Nodal Marginal Zone Lymphomas

Expression of CD137 in Tumor Cells of Hodgkin Lymphoma from Northern China and Its Application in Pathological Differential Diagnosis

Diagnostic Utility of the B-cell Lineage Markers CD20, CD79a, PAX5, and CD19 in Paraffin-embedded Tissues From Lymphoid Neoplasms

Basic immunohistochemistry for lymphoma diagnosis

Study of Expression of CD23 on Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus

Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice

Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas

Study on Expression of CD23 on Peripheral Blood Mononuclear Cells in Psoriasis

Expression of Cathepsin-D in Hodgkin Lymphoma and Its Significance

Expression of Langerin in and Its Diagnostic Value for Langerhans Cell Histiocytosis

Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen

[Relationship Between Lymphocyte Immunophenotypes and Histologic Subtypes of Hodgkin's Lymphoma and Its Significance].

CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones

[Immunohistochemical Study Using T-cell Lymphoma Antibody 1 and CD44 in Diagnosis of Burkitt's Lymphoma].